Connect with us

BioPharma

Artificial Intelligence Technology Solutions Inc. (OTCMKTS: AITX) Major Run Northbound Brewing as AI Innovator Reports Record Q2 Revenues

Published

on

Artificial Intelligence Technology Solutions Inc. (OTCMKTS: AITX) is making an explosive move up the charts after the Company reported revenues of $701,906 for the six months ended August 31, 2021. The Company also reported device subscription revenues, referred to as Recurring Monthly Revenue (RMR), increased 69% over the same period of the prior year in Q2, 2021. AITX is quickly transforming into a volume leader in small caps trading $7 million in dollar volume on Tuesday alone. The stock is getting noticed by some big players in small caps and at current levels has plenty of room to grow. Currently under heavy accumulation AITX is looking to blaze a path along the likes of Enzolytics or Tesoro and break out into a whole new dimension – Tesoro went to multi dollars – AITX is moving up with power and has a significant gap to fill from here. The price to beat is recent highs of $0.2899; a break over and its blue skies ahead for AITX. 

AITX management has been working hard behind the scenes recently completing actions to eliminate almost all of its dilutive financial instruments. Unless subsequent events reinstate a dilutive financial instrument, none of which are under consideration, the number of outstanding shares of the company will only grow as a result of actions related to the effective and current S-3. The Company’s subsidiarity RAD continues to receive significant orders for its lineup of RAD devices including from Fortune 500 companies. Recently the Company announced its new lineup of RAD 3.0 devices. RAD 3.0 marks a complete design and re-engineering of nearly all RAD solutions. The response to the RAD 3.0 announcements has been overwhelmingly positive and management expects significant new orders once its customers see the new lineup in person. The stock has momentum, huge liquidity and legions of new shareholders bidding up the price with a significant gap to fill from current levels to $0.2899. 

Artificial Intelligence Technology Solutions Inc. (OTCMKTS: AITX) is an innovator in the delivery of artificial intelligence-based solutions that empower organizations to gain new insight, solve complex challenges and fuel new business ideas. Through its next-generation robotic product offerings, AITX’s RAD and RAD-M companies help organizations streamline operations, increase ROI and strengthen business. AITX is an innovator in the delivery of artificial intelligence-based solutions that empower organizations to gain new insight, solve complex challenges and fuel new business ideas. Through its next-generation robotic product offerings, AITX’s RAD and RAD-M companies help organizations streamline operations, increase ROI and strengthen business. AITX technology improves the simplicity and economics of patrolling and guard services, and allows experienced personnel to focus on more strategic tasks. Customers augment the capabilities of existing staffs and gain higher levels of situational awareness, all at drastically reduced cost. AITX solutions are well suited for use in multiple industries such as enterprises, government, transportation, critical infrastructure, education and healthcare.

The Company through its subsidiary, Robotic Assistance Devices, Inc. (RAD), is looking to redefine $25 billion (US) security and guarding services industry through its broad lineup of innovative, AI-driven Solutions-as-a-Service business model. RAD solutions are specifically designed to provide a cost savings to businesses of between 35%-80% when compared to the industry’s existing and costly manned security guarding and monitoring model. RAD delivers this tremendous costs savings via a suite of stationary and mobile robotic solutions that complement, and at times, directly replace the need for human personnel in environments better suited for machines. All RAD technologies, AI-based analytics and software platforms are developed in-house.

Earlier this year AITX announced that its wholly owned subsidiary Robotic Assistance Devices (RAD) has entered into an agreement with Civitas PSG, one of the largest security companies in Romania. Through this agreement, Civitas broadens its offering to include RAD’s autonomous remote security solutions. Specifics of the agreement were not disclosed, but the company confirmed that the agreement covers all RAD security devices, mobile and stationary, including the recently announced ROAMEO mobile robot and Wally HSO, actively being deployed for health screening, health monitoring and face covering detections operations. “We are excited to provide RAD’s innovative security solutions to our clients,” said Rene Pasculescu, CEO at Civitas Group. “Our current security clients, as well as those looking to elevate their security situation, can now deploy any one of these remarkable and cost-saving RAD devices.”

Microcapdaily has reported on AITX before; on January 31, 2021 we stated: “The Company also received an opening purchase agreement from Civitas PSG, one of the largest security companies in Romania for (2) RAD devices and received a previously anticipated order for a 5-unit RAD solution. This order was received via one of RAD’s significant North American dealers. A mix of SCOT, Wally and ROSA units will form a fully-integrated autonomous system, providing a secured distribution warehouse exclusively utilizing RAD solutions. AITX management has been working hard behind the scenes recently restructuring the vast majority of its debt, which has saved the company a tremendous amount of dilution. The Company’s subsidiarity RAD also received a greatly anticipated order for a 5-unit RAD solution. This integrated autonomous remote security and access solution will be deployed to a Fortune 500 end-user client with over 10 distribution centers and over 7,500 retail locations in the U.S. and Puerto Rico. 

Robotic Assistance Devices (RAD) delivers artificial intelligence-based security robotic solutions that empower organizations to gain new insight, solve complex challenges and fuel new business ideas. Its first product suite helps organizations improve the simplicity and economics of patrolling and guard services while harnessing the power of artificial intelligence to gain enhanced situational awareness that improves security, all at a drastically reduced cost. For a full list of RAD Products go here these include the ROAMEO a rugged observation assistance mobile electronic officer, AVA autonomous verifed access, ROSA180 a responsive observation security agent wtih 180 degree field of view, ROSA270 a responsive observation security agent with 270 degree field of view, WALLY a wall mounted version of SCOT, SCOT a secuerity control observation tower and WALLY HSO a health screening the RAD way.

AITX ROAMEO™ 3.0 is Ready for Patrol! ROAMEO is an outdoor security robot unlike any deployed to date. ROAMEO takes all of RAD’s industry-leading AI analytics, video surveillance capabilities, and interactive communications and puts them on the move, at speeds of up to 12 mph. ROAMEO’s 360-degree field-of-view routed through a robust analytic suite, all documented (HIPAA-compliant) securely on the cloud through enhanced cellular services will allow ROAMEO to map property patrol sites, plan and execute routes, avoid obstacles (i.e., people, trees, power posts), and collect and apply data to further optimize for precision and efficiency. The AI analytic suite powering ROAMEO enables the unit to identify vehicles, license plate numbers, and people, with facial recognition, even people wearing or not wearing face masks. As an added benefit, ROAMEO will also interact with people along its patrol route, providing necessary calls for help, panic buttons, security alerts, etc., plus an unlimited number of concierge services including local information, weather, directions, plus profit-generating advertising messaging. 

 To Find out the inside Scoop on AITX Subscribe to Microcapdaily.com Right Now by entering your Email in the box below

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

AITX

AITX is making an explosive move up the charts after the Company reported revenues of $701,906 for the six months ended August 31, 2021. The Company also reported device subscription revenues, referred to as Recurring Monthly Revenue (RMR), increased 69% over the same period of the prior year in Q2, 2021.  

The Company completed actions to eliminate almost all of its dilutive financial instruments as follows: 1. Substantially all of the convertible debt has been paid or converted; 2. The number of Series F convertible preferred Shares were reduced; 3. An agreement was reached amongst all Series F shareholders not to convert their shares prior to August 2023, unless there is an uplisting of the Company’s stock or an asset sale. Unless subsequent events reinstate a dilutive financial instrument, none of which are under consideration, the number of outstanding shares of the company will only grow as a result of actions related to the effective and current S-3. 

Artificial Intelligence Technology Solutions Announces Regulation Crowdfunding for Robotic Assistance Devices Mobile Subsidiary - RAD•M the home of ROAMEOOn Wednesday, October 13, 2021, the Company announced its new lineup of RAD 3.0 devices. RAD 3.0 marks a complete design and re-engineering of nearly all RAD solutions. “The entire RAD team worked feverishly hard throughout Q2 so that we could preview all of the improvements in design and performance that we showcased earlier this week,” Reinharz added. “The response to our RAD 3.0 announcements has been overwhelmingly positive. I’m sure that we have a hit on our hands and we cannot wait for our customers to see these in person. The AITX Investors Open House and RAD 3.0 Reveal video is available for viewing at https://tinyurl.com/hkp5ds 

Steve Reinharz, President and CEO of AITX stated: “The first half of our fiscal year saw continued progress, development, plus exponential sales growth. Both subscription revenues and sales revenues saw dramatic increases year over year. Fiscal year 2022 continues to confirm RAD’s inevitable progress. These second quarter results reveal our constant grind, whether it’s inventing new products, penetrating new markets, or solidifying our financial position. There is so much more on the immediate horizon that we expect to conquer, making FY 2022 an incredibly big year for us in sales, team, tech and industry stature.” 

For More on AITX Subscribe Right Now!

AITX is making an explosive move up the charts after the Company reported revenues of $701,906 for the six months ended August 31, 2021. The Company also reported device subscription revenues, referred to as Recurring Monthly Revenue (RMR), increased 69% over the same period of the prior year in Q2, 2021. AITX is quickly transforming into a volume leader in small caps trading $7 million in dollar volume on Tuesday alone. The stock is getting noticed by some big players in small caps and at current levels has plenty of room to grow. Currently under heavy accumulation AITX is looking to blaze a path along the likes of Enzolytics or Tesoro and break out into a whole new dimension – Tesoro went to multi dollars – AITX is moving up with power and has a significant gap to fill from here. The price to beat is recent highs of $0.2899; a break over and its blue skies ahead. AITX management has been working hard behind the scenes recently completing actions to eliminate almost all of its dilutive financial instruments. Unless subsequent events reinstate a dilutive financial instrument, none of which are under consideration, the number of outstanding shares of the company will only grow as a result of actions related to the effective and current S-3. The Company’s subsidiarity RAD continues to receive significant orders for its lineup of RAD devices including from Fortune 500 companies. Recently the Company announced its new lineup of RAD 3.0 devices. RAD 3.0 marks a complete design and re-engineering of nearly all RAD solutions. The response to the RAD 3.0 announcements has been overwhelmingly positive and management expects significant new orders once its customers see the new lineup in person. The stock has momentum, huge liquidity and legions of new shareholders bidding up the price with a significant gap to fill from current levels to $0.2899. We will be updating on AITX when more details emerge so make sure you are subscribed to Microcapdaily so you know what’s going on with AITX.

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Disclosure: we hold no position in AITX either long or short and we have not been compensated for this article.

BioPharma

Advancing Medical Frontiers: Elutia Inc.’s(NASDAQ: ELUT) Strategic Vision in a $600 Million Market

Published

on

Elutia Inc (NASDAQ: ELUT) shares bolstered a whopping 33% today as the company recently shared that they’ve secured about $10.5 million in funding through a private investment round. If all the warrants are cashed in as part of this funding, the total could go up to $26.2 million.

Latest Changes:

Just last week, Aziyo Biologics changed its name to Elutia Inc. Following this change, Elutia made an announcement about selling its Orthobiologics business unit to Berkeley Biologics, a subsidiary of GNI Group Ltd. This move is set to bring in a substantial amount of cash, totalling up to $35 million for Elutia. This sum includes a notable upfront payment of $15 million, plus additional potential earnings of up to $20 million over five years. The deal is expected to be finalized in the fourth quarter of 2023.

This sale is a big step for Elutia, especially in the realm of drug-eluting biomatrix technology (DEB). Elutia is actively seeking approval from the FDA for their main product, CanGaroo RM. This product utilizes innovative biomatrix technology with antibiotics rifampin and minocycline (RM), providing long-term protection for cardiac pacemakers and defibrillators. This tackles a huge market estimated to be worth around 600 million. Elutia is aiming to introduce CanGaroo RM to the market in the first half of 2024.

Subscribe to Microcapdaily.com Right Now by entering your Email in the box below. 

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Standard Of Care:

Medtronic (NYSE: MDT) stands as the exclusive provider of the antibiotic envelope within the current market. This envelope is crafted using synthetic mesh infused with antibiotics. Back in 2014, Medtronic acquired this technology, making a strategic investment of up to $200 million. Primarily intended for Cardiac Implantable Electronic Device (CIED) revision procedures, this product boasts estimated annual sales in the range of $250 to $300 million.

However, despite its market presence and revenue generation, the Medtronic antibiotic envelope has notable limitations. While it effectively combats infections, its synthetic composition renders it less effective in supporting wound healing. Moreover, it poses challenges in accommodating larger devices like Subcutaneous Implantable Defibrillators (SCID).

Drug-eluting biomatrix (DEB):

Drug-eluting biomatrix (DEB) involves a specialized approach to drug delivery using a biomatrix as a carrier or platform. In simple terms, it’s a technique where a biomaterial matrix, often a biocompatible polymer or similar substance, is used to release drugs in a controlled and targeted manner.

The biomatrix acts as a support structure that can hold and gradually release drugs or therapeutic agents at a specific site in the body, typically over an extended period. This is particularly useful in medical applications where a localized and sustained delivery of medication is necessary.

For instance, in the context of Elutia’s CanGaroo RM, a biomatrix incorporating antibiotics rifampin and minocycline is used to provide prolonged protection for cardiac pacemakers and defibrillators. The biomatrix slowly releases these antibiotics at the surgical site, preventing infections and promoting healing.

DEB technology is gaining traction because it enhances treatment efficiency by ensuring the drug is delivered directly to the target area, minimizing side effects, and optimizing therapeutic outcomes. It’s a promising approach in the field of medical advancements, especially in areas like cardiology, oncology, and orthopedics.

Post-mastectomy Breast Reconstruction:

On top of this, the company also has plans to develop an RM version of its SimpliDerm biomatrix tailored for breast reconstruction procedures. The rate of infections after this surgery is quite high, more than 10%, highlighting a big medical need in a market valued at over $500 million. Elutia is stepping up to address this issue by developing SimpliDerm® RM, which incorporates their unique DEB technology. The funds raised through the private investment round (PIPE) and the sale of the Orthobiologics business unit will not only boost Elutia’s efforts in advancing their drug-eluting biomatrix products for the cardiac pacemaker and defibrillator market, but also for post-mastectomy breast reconstruction.

What’s next:

As mentioned earlier, their biomatrix platform serves two major markets. CanGaroo RM, their upcoming product, is slated for a 1H of 2024 market release and is poised to be a pioneer in a $600 million market. Furthermore, their SimpliDerm RM product utilizes the same proprietary antibiotic-eluting technology found in CanGaroo RM, which serves a 1.6B market according to their presentation deck. They aim to secure an IDE by Q4 2024, and upon achieving these milestones, they plan to venture into neurostimulator markets, particularly in pain management, to further drive their growth.

We will update you on ELUT when more details emerge, subscribe to Microcapdaily to follow along!

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Disclosure: We have not been compensated for this article/video. MicroCap Daily is not an investment advisor; this article/video does not provide investment advice. Always do your research, make your own investment decisions, or consult with your nearest financial advisor. This article/video is not a solicitation or recommendation to buy, sell, or hold securities. This article/video is our opinion, is meant for informational and educational purposes only, and does not provide investment advice. Past performance is not indicative of future performance.

Picture by sasint from Pixabay

Continue Reading

BioPharma

ZyVersa Therapeutics’ (NASDAQ: ZVSA) Breakthrough: A Super Tool for Tackling Inflammation in ALS and Beyond

Published

on

ZyVersa Therapeutics (NASDAQ: ZVSA) had a spectacular day on the market, with its stock surging by almost 50% following a significant announcement about one of their promising drug candidates, IC-100. This drug is designed to combat inflammation in the context of Inflammatory Diseases, and the latest data is incredibly promising. For those who are new to this field of investment, we’ve taken the liberty of rephrasing the press release in simpler terms.

The Release:

When you’re dealing with diseases like ALS that affect your brain and nerves, shutting down the inflammasome pathway NLRP3 (a multi-protein that regulates the immune system and inflammatory signaling), is not enough.

To address this, ZyVersa is working on something called Inflammasome ASC Inhibitor IC-100. It’s like a super tool designed to block not just NLRP3 but a bunch of other inflammasome pathways too – up to 12 of them. This helps keep inflammation in check, whether it’s in the central nervous system (CNS) or other parts of the body where inflammation is causing problems.

Subscribe to Microcapdaily.com Right Now by entering your Email in the box below.

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

In a recent paper published in Frontiers in Immunology, they pointed out that focusing only on NLRP3 might not do the trick when it comes to calming CNS inflammation in ALS and similar diseases. They did experiments with cells and even used mice to back up their point. Turns out, just targeting NLRP3 didn’t stop the release of those pesky proinflammatory chemicals or the damage they were causing in the spinal cord.

The authors of the paper basically said, “Maybe we should aim to tackle multiple inflammasome pathways when it comes to diseases like ALS, where lots of inflammasomes are going haywire.”

The CEO and president at ZyVersa, Stephen C. Glover mentioned “Our research shows that to really put the brakes on inflammation driven by multiple inflammasomes, we need more than just NLRP3 inhibition.” He added that IC-100 is like a superhero in the world of inflammation control. It stops the formation of different types of inflammasomes, preventing the start of the inflammation chain reaction, and also puts a halt to something called ASC specks, which keep the inflammation going. You can dive deeper into how IC 100 works by checking out their website here.

So, in plain speak, ZyVersa is cooking up a promising solution for folks dealing with inflammation-related problems, especially those tied to the brain and nerves. They’re not just focusing on one troublemaker; they’re going after a whole gang to keep things under control.

Overall ZyVersa is a company on a mission to create groundbreaking treatments for kidney and inflammatory diseases, and IC-100 could help them in this mission.

We will update you on ZVSA when more details emerge, subscribe to Microcapdaily to follow along!

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Disclosure: We have not been compensated for this article/video. MicroCap Daily is not an investment advisor; this article/video does not provide investment advice. Always do your research, make your own investment decisions, or consult with your nearest financial advisor. This article/video is not a solicitation or recommendation to buy, sell, or hold securities. This article/video is our opinion, is meant for informational and educational purposes only, and does not provide investment advice. Past performance is not indicative of future performance.

Picture by swiftsciencewriting from Pixabay

Continue Reading

BioPharma

Creative Medical Technology NASDAQ: CELZ) Major Breakthrough: Allogeneic Cell Line Paves the Way for Diabetes Treatment

Published

on

Creative Medical Technology Holdings, Inc. (NASDAQ: CELZ) has recently seen a substantial intraday gain of over 15% in its share price. Despite the absence of any recent news or filings, this surge could suggest significant progress in the realm of allogeneic cell therapy.

Background:

The company is known for its regenerative approaches in various medical areas, including immunotherapy, endocrinology, urology, gynecology, and orthopedics, and made a significant announcement. In the fourth quarter of 2022,They successfully developed a new allogeneic cell line called AlloStem™. AlloStem™ is derived from human perinatal tissue and includes a Master Cell Bank and a Drug Master File. Now, with FDA approval, their program, known as CELZ-201, is being used in an early clinical trial for type 1 diabetes and will continue to be developed for both type 1 and type 2 diabetes treatment.

Additionally, the company is using the AlloStem™ line for its StemSpine® procedure to help treat chronic back pain. They report remarkable results, including over a 90% reduction in narcotic usage, more than an 80% reduction in pain scores, and over a 50% reduction in the Oswestry score in patients treated with AlloStem™.

Subscribe to Microcapdaily.com Right Now by entering your Email in the box below.

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Allogeneic Cell Therapy:

Allogeneic Cell Therapy is a treatment that uses cells from healthy donors to treat patients with otherwise untreatable diseases. These cells can come from various sources, like bone marrow, blood, or umbilical cord blood. This approach shows great promise in the medical field.

Allogeneic cell therapy offers potentially curative options for patients when traditional treatments fall short. While still a relatively new field, ongoing research into allogeneic cell therapies holds great potential for patients suffering from these diseases. Companies like Argan Inc. are also exploring the benefits of allogeneic cells.

With FDA approval and ongoing clinical trials, Creative Medical Technology’s recent developments open doors to innovative treatments that could significantly enhance the lives of those dealing with diabetes and other diseases. The global market for allogeneic cell therapy reached $255.6 million in 2022 and is expected to grow at a rate of 27.4% from 2023 to 2030, emphasizing the importance of continued research. As the company remains dedicated to medical innovation, their efforts have the potential to improve the health outcomes of people worldwide.

Latest Release:

The company recently shared key updates on its financial status and drug pipeline for Q3 2023. The biotech company, known for its regenerative medical solutions, reported being debt-free with $14.6 million in cash and $14.4 million in working capital, sufficient to cover expenses through 2024.

Their advancements in treating type 1 diabetes include FDA clearance for a groundbreaking clinical trial using CELZ-201 (AlloStem™). The company obtained Institutional Review Board approval and partnered with Syneos Health for this study. They also filed for Orphan Drug Designation to tackle brittle type 1 diabetes.

Promising results emerged from the CELZ-001 treatment for type 2 diabetes, demonstrating substantial reductions in insulin requirements with no safety concerns.

A pilot study on the StemSpine® procedure, using donor cells (AlloStem), showed impressive reductions in narcotic usage, pain scores, and improved functionality for chronic lower back pain patients.

Creative Medical Technology’s ImmCelz platform proved efficient, requiring fewer donor cells and yielding high-quality results.

They also collaborated with Greenstone Biosciences Inc. to develop a human-induced pluripotent stem cell (iPSC) pipeline, iPScelzTM, aimed at expediting drug discovery. The development of this cell line is expected to save the company two to three years in research and development time, along with associated expenses. Additionally, it will accelerate its drug discovery program by leveraging artificial intelligence.

We will update you on CELZ when more details emerge, subscribe to Microcapdaily to follow along!

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Disclosure: We have not been compensated for this article/video. MicroCap Daily is not an investment advisor; this article/video does not provide investment advice. Always do your research, make your own investment decisions, or consult with your nearest financial advisor. This article/video is not a solicitation or recommendation to buy, sell, or hold securities. This article/video is our opinion, is meant for informational and educational purposes only, and does not provide investment advice. Past performance is not indicative of future performance.

Picture by stevepb from Pixabay

 

 

Continue Reading

Trending

© All rights reserved.

Sign up now for our 100% FREE Penny Stock Newsletter

Privacy Policy. we will never share your email with anyone.